Geneva, Switzerland and Boston, MA - February 1, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage
biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that
compromise a woman's reproductive health and pregnancy, today announced that Dr. Ernest Loumaye, co-founder and CEO of ObsEva (the
"Company"), has returned to work following a personal leave for medical reasons.
Dr. Frank Verwiel, the Company's Chairperson of the Board of Directors, stated "The Board of Directors is delighted that Ernest
has made a speedy recovery and returned full time to his role of CEO."
Dr. Ernest Loumaye extends his gratitude to Dr Frank Verwiel and the Office of the CEO for overseeing the operations of the
Company during his absence and stated that he is elated to return to lead the Company towards the delivery of several important
milestones in 2018.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel
therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and
disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating
endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and
is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
Media Contact:
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
202-955-6222 x2526
CEO Office contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/3ddee889-e267-4c10-a7d7-168b32aaf709
